CoChat
Sign Up
Cited by 1,132Ovarian function and disordersSexual Differentiation and DisordersAdrenal Hormones and Disorders

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Androgen Excess in Women: Experience with Over 1000 Consecutive Patients

Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., Boots, L. R.·2004·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2003-031122
Open this paper in CoChat — free account

Abstract

The objective of the present study was to estimate the prevalence of the different pathological conditions causing clinically evident androgen excess and to document the degree of long-term success of suppressive and/or antiandrogen hormonal therapy in a large consecutive population of patients. All patients presenting for evaluation of symptoms potentially related to androgen excess between October 1987 and June 2002 were evaluated, and the data were maintained prospectively in a computerized database. For the assessment of therapeutic response, a retrospective review of the medical chart was performed, after the exclusion of those patients seeking fertility therapy only, or with inadequate follow-up or poor compliance. A total of 1281 consecutive patients were seen during the study period. Excluded from analysis were 408 patients in whom we were unable to evaluate hormonal status, determine ovulatory status, or find any evidence of androgen excess. In the remaining population of 873 patients, the unbiased prevalence of androgen-secreting neoplasms was 0.2%, 21-hydroxylase-deficient classic adrenal hyperplasia (CAH) was 0.6%, 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) was 1.6%, hyperandrogenic insulin-resistant acanthosis nigricans (HAIRAN) syndrome was 3.1%, idiopathic hirsutism was 4.7%, and polycystic ovary syndrome (PCOS) was 82.0%. Fifty-nine (6.75%) patients had elevated androgen levels and hirsutism but normal ovulation. A total of 257 patients were included in the assessment of the response to hormonal therapy. The mean duration of follow-up was 33.5 months (range, 6-155). Hirsutism improved in 86%, menstrual dysfunction in 80%, acne in 81%, and hair loss in 33% of patients. The major side effects noted were irregular vaginal bleeding (16.1%), nausea (13.0%), and headaches (12.6%); only 36.6% of patients never complained of side effects. In this large study of consecutive patients presenting with clinically evident androgen excess, specific identifiable disorders (NCAH, CAH, HAIRAN syndrome, and androgen-secreting neoplasms) were observed in approximately 7% of subjects, whereas functional androgen excess, principally PCOS, was observed in the remainder. Hirsutism, menstrual dysfunction, or acne, but not alopecia, improved in the majority of patients treated with a combination suppressive therapy; although more than 60% experienced side effects.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2003-031122

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 60 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R.
Affiliations
University of Alabama at Birmingham (US)
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2004-02
Volume
89
Issue
2
Pages
453-462
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2003-031122
OpenAlex
W2163069137
Cited by
1,132
References
60
Citations by year
2026: 19 · 2025: 33 · 2024: 35 · 2023: 36 · 2022: 53 · 2021: 34 · 2020: 48 · 2019: 41 · 2018: 279 · 2017: 62 · 2016: 39 · 2015: 65 · 2014: 51 · 2013: 50 · 2012: 45
FWCI
31.82
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • University of Alabama at Birmingham
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (K24-DK01346)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD029364, R01-HD29364)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
hyperandrogenism, polycystic ovary syndrome, hirsutism, 21-hydroxylase deficiency, adrenal hyperplasia, insulin resistance, antiandrogen therapy, hormone therapy response, prevalence, acne, menstrual disorders, hair loss, treatment side effects, long-term follow-up
MeSH terms
Acanthosis Nigricans, Adrenal Hyperplasia, Congenital, Adult, Androgen Antagonists, Androgens, Endocrine Gland Neoplasms, Female, Humans, Retrospective Studies, Time Factors, Prevalence, Treatment Outcome, Hyperandrogenism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review